Meeder Advisory Services Inc. Takes $492,000 Position in Illumina, Inc. $ILMN

Meeder Advisory Services Inc. bought a new position in shares of Illumina, Inc. (NASDAQ:ILMN) in the 2nd quarter, according to its most recent disclosure with the SEC. The institutional investor bought 2,800 shares of the life sciences company’s stock, valued at approximately $492,000.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in the business. BlackRock Inc. acquired a new position in shares of Illumina during the 2nd quarter worth about $3,374,423,000. Plato Investment Management Ltd acquired a new stake in Illumina in the 2nd quarter worth about $948,000. Impact Partnership Wealth LLC boosted its holdings in Illumina by 235.8% in the 1st quarter. Impact Partnership Wealth LLC now owns 11,080 shares of the life sciences company’s stock worth $1,366,000 after buying an additional 7,780 shares during the last quarter. Insight Wealth Strategies LLC purchased a new stake in Illumina during the 2nd quarter worth approximately $6,062,000. Finally, Perigon Wealth Management LLC acquired a new position in shares of Illumina during the second quarter valued at approximately $1,004,000. Hedge funds and other institutional investors own 89.42% of the company’s stock.

Insiders Place Their Bets

In other news, CAO Scott D. Ericksen sold 500 shares of Illumina stock in a transaction on Friday, May 29th. The stock was sold at an average price of $160.00, for a total transaction of $80,000.00. Following the transaction, the chief accounting officer owned 14,446 shares in the company, valued at $2,311,360. The trade was a 3.35% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Christensen Jakob Wedel sold 1,033 shares of the business’s stock in a transaction dated Tuesday, August 18th. The shares were sold at an average price of $191.52, for a total transaction of $197,840.16. Following the transaction, the senior vice president directly owned 14,023 shares in the company, valued at approximately $2,685,684.96. The trade was a 6.86% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders sold 1,416,384 shares of company stock worth $256,164,151. 2.90% of the stock is currently owned by company insiders.

Illumina Price Performance

ILMN stock opened at $213.24 on Friday. The company has a debt-to-equity ratio of 0.53, a current ratio of 1.80 and a quick ratio of 1.40. The business has a 50 day simple moving average of $186.84 and a 200-day simple moving average of $151.97. The firm has a market capitalization of $32.20 billion, a PE ratio of 39.78, a price-to-earnings-growth ratio of 2.89 and a beta of 1.45. Illumina, Inc. has a 1 year low of $88.00 and a 1 year high of $220.32.

Illumina (NASDAQ:ILMN) last announced its quarterly earnings data on Thursday, July 30th. The life sciences company reported $1.31 EPS for the quarter, topping analysts’ consensus estimates of $1.23 by $0.08. The firm had revenue of $1.16 billion for the quarter, compared to the consensus estimate of $1.13 billion. Illumina had a return on equity of 29.84% and a net margin of 18.36%.The firm’s revenue was up 9.4% compared to the same quarter last year. During the same quarter last year, the business posted $1.19 earnings per share. Illumina has set its FY 2026 guidance at 5.300-5.400 EPS. Equities research analysts anticipate that Illumina, Inc. will post 5.36 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities analysts have recently weighed in on the company. Leerink Partners raised their target price on Illumina from $175.00 to $210.00 and gave the company an “outperform” rating in a research report on Friday, July 17th. Wall Street Zen raised Illumina from a “hold” rating to a “buy” rating in a research note on Saturday, August 1st. Deutsche Bank Aktiengesellschaft lowered Illumina to a “hold” rating in a report on Wednesday, August 5th. Sanford C. Bernstein reaffirmed a “market perform” rating and set a $215.00 target price on shares of Illumina in a research note on Friday, July 31st. Finally, Stifel Nicolaus upped their target price on shares of Illumina from $155.00 to $225.00 and gave the stock a “buy” rating in a report on Friday, July 31st. One analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, six have issued a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $188.40.

Illumina Company Profile

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.